WikiMini

ZK-283197

ZK-283197
Clinical data
Other namesBAY 86-5310; SH-T04211C; ZK283197
Routes of
administration		By mouth[1]
Drug classEstrogen; Selective ERβ agonist
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
PubChem SID
UNII
Chemical and physical data
FormulaC20H25FO2
Molar mass316.416 g·mol−1
3D model (JSmol)
  • C[C@]12CC[C@]3([C@H]([C@@H]1C[C@H]([C@@H]2F)O)CCC4=C3C=CC(=C4)O)C=C
  • InChI=1S/C20H25FO2/c1-3-20-9-8-19(2)16(11-17(23)18(19)21)15(20)6-4-12-10-13(22)5-7-14(12)20/h3,5,7,10,15-18,22-23H,1,4,6,8-9,11H2,2H3/t15-,16-,17+,18-,19-,20+/m0/s1
  • Key:LXLNOGZWGYFWQV-CFSBILQPSA-N

ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms.[1][2] It reached phase II clinical trials prior to the discontinuation of its development.[1] Its development was terminated in 2014.[1]

References

[edit]
  1. ^ a b c d "ZK 283197". AdisInsight. Springer Nature Switzerland AG.
  2. ^ US 332204, Pietras RJ, Jung ME, "Methods of using estrogen receptor-beta ligands as radiation mitigators", published 2015-01-15 


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.